Ed J. Griffen obtained his Ph.D. from Imperial College, London, and undertook postdoctoral research at the University of Waterloo-Kitchener, Canada. He joined Zeneca Pharmaceuticals as a team leader in medicinal chemistry working in the CNS, infection, oncology, and chemical biology areas. During a secondment into the computational chemistry group, he co-developed matched molecular pair tools to quantify medicinal chemistry approaches. In 2012 he was a cofounder of MedChemica Ltd. He has taught medicinal chemistry courses at the University of Manchester and in France, and India. He is a named inventor on 16 patents and co-authored more than 26 articles, book chapters, and a textbook with over 1300 citations. He has worked on 4 projects that have entered clinical development. In March 2020 he joined the COVID Moonshot international team as the Design Team Leader which has a lead compound progressing though pre-clinical development toward Phase 1 testing funded by the Wellcome Trust. In 2022 he became the Principal Investigator for Lead Optimisation in the NIH funded ASAP Pandemic Preparedness U19 AViDD centre. His interests are in delivering new medicines faster through data driven decision making and medicinal chemistry education.

Jess Stacey completed an MChem with an Industrial Placement from Newcastle University in 2017, where she first was introduced to chemoinformatics at her placement with MedChemica. Jess then went to Sheffield to undertake a PhD in chemoinformatics under the supervision of Professor Val Gillet and Stephen Pickett (GSK), which entitled “Data Mining for Lead Optimisation”. In November 2022 she returned to MedChemica. Since then, she has created a matched molecular pair scaffold hopping tool, CoreDesign®. For the past year Jess has been part of the ASAP consortium where she has been designing new compounds within the lead optimisation stage, which has led her to her most recent work on time series analysis of the SAR around the most promising scaffold.

Ed J. Griffen obtained his Ph.D. from Imperial College, London, and undertook postdoctoral research at the University of Waterloo-Kitchener, Canada. He joined Zeneca Pharmaceuticals as a team leader in medicinal chemistry working in the CNS, infection, oncology, and chemical biology areas. During a secondment into the computational chemistry group, he co-developed matched molecular pair tools to quantify medicinal chemistry approaches. In 2012 he was a cofounder of MedChemica Ltd. He has taught medicinal chemistry courses at the University of Manchester and in France, and India. He is a named inventor on 16 patents and co-authored more than 26 articles, book chapters, and a textbook with over 1300 citations. He has worked on 4 projects that have entered clinical development. In March 2020 he joined the COVID Moonshot international team as the Design Team Leader which has a lead compound progressing though pre-clinical development toward Phase 1 testing funded by the Wellcome Trust. In 2022 he became the Principal Investigator for Lead Optimisation in the NIH funded ASAP Pandemic Preparedness U19 AViDD centre. His interests are in delivering new medicines faster through data driven decision making and medicinal chemistry education.

Jess Stacey completed an MChem with an Industrial Placement from Newcastle University in 2017, where she first was introduced to chemoinformatics at her placement with MedChemica. Jess then went to Sheffield to undertake a PhD in chemoinformatics under the supervision of Professor Val Gillet and Stephen Pickett (GSK), which entitled “Data Mining for Lead Optimisation”. In November 2022 she returned to MedChemica. Since then, she has created a matched molecular pair scaffold hopping tool, CoreDesign®. For the past year Jess has been part of the ASAP consortium where she has been designing new compounds within the lead optimisation stage, which has led her to her most recent work on time series analysis of the SAR around the most promising scaffold.